Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS)
Thyroid2013Vol. 24(5), pp. 832–839
Citations Over TimeTop 1% of 2013 papers
Allen S. Ho, Evan E. Sarti, Kunal Jain, Hangjun Wang, Iain J. Nixon, Ashok R. Shaha, Jatin P. Shah, Dennis H. Kraus, Ronald Ghossein, Stephanie Fish, Richard J. Wong, Oscar Lin, Luc G.T. Morris
Abstract
In patients presenting to a comprehensive cancer center, malignancy rates in nodules with AUS/FLUS cytology are higher than previously estimated, with 26.6-37.8% of AUS/FLUS nodules harboring cancer. These data imply that Bethesda Category III nodules in some practice settings may have a higher risk of malignancy than traditionally believed, and that guidelines recommending repeat FNA or observation merit reconsideration.
Related Papers
- → Natural History of Benign Solid and Cystic Thyroid Nodules(2003)277 cited
- → Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes(2017)75 cited
- → Fate of untreated benign thyroid nodules: Results of long‐term follow‐up(1994)140 cited
- → <p>Fine-Needle Aspiration of Subcentimeter Thyroid Nodules in the Real-World Management</p>(2020)4 cited
- → Surveillance of Benign Thyroid Nodules(2017)